PMID- 26230522
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20181113
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 182
IP  - 1
DP  - 2015 Oct
TI  - Streptococcus pneumoniae antibody titres in patients with primary antibody 
      deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous 
      immunoglobulin (SCIG).
PG  - 51-6
LID - 10.1111/cei.12665 [doi]
AB  - Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are 
      effective in the treatment of patients with primary antibody deficiency disorders 
      (PAD). The purpose of this study was to evaluate Streptococcus pneumoniae (Spn) 
      antibody titres to 14 serotypes in patients receiving IVIG compared to SCIG and 
      to correlate Spn antibody levels to clinical outcome. The doses of immunoglobulin 
      (Ig)G/kg/month were similar in both IVIG and SCIG groups. In 11 patients treated 
      with IVIG, Spn antibody titres were >/= 1.3 mug/ml to 99.4 +/- 2.1% of the 14 
      serotypes at peak IVIG but decreased to 66.9 +/- 19.8% at trough IVIG. Loss of Spn 
      titres >/= 1.3 mug/ml was most frequent for Spn serotypes 1, 4, 9V and 23. This 
      correlated with lower Spn antibody titres to these serotypes at peak IVIG 
      compared to the other serotypes. In 13 patients treated with SCIG, Spn antibody 
      titres were protective to 58.2 +/- 23.3% of the serotypes 3-5 days after infusion, 
      similar to trough IVIG. Similarly, the Spn serotypes with the least protective 
      percentages were the same as the ones observed in trough IVIG. There were no 
      annualized serious bacterial infections (aSBI) in either group. However, there 
      were significantly decreased annualized other infections (aOI) in the SCIG group 
      compared to the IVIG-treated group, 0.8 +/- 0.7 versus 2.2 +/- 1.2 
      infections/patient/year (P = 0.004). Breakthrough aOI did not correlate with 
      protective or higher serum Spn antibody titres.
CI  - (c) 2015 British Society for Immunology.
FAU - Knutsen, A P
AU  - Knutsen AP
AD  - Department of Pediatrics, Division Allergy & Immunology, Jeffrey Modell 
      Diagnostic Center for Primary Immunodeficiencies, Saint Louis University, St 
      Louis, MO.
FAU - Leiva, L E
AU  - Leiva LE
AD  - Department of Pediatrics, Allergy/Immunology Division, Jeffrey Modell Diagnostic 
      Center for Primary Immunodeficiencies, Louisiana State University Health Sciences 
      Center, New Orleans, LA, USA.
FAU - Caruthers, C
AU  - Caruthers C
AD  - Department of Pediatrics, Division Allergy & Immunology, Jeffrey Modell 
      Diagnostic Center for Primary Immunodeficiencies, Saint Louis University, St 
      Louis, MO.
FAU - Rodrigues, J
AU  - Rodrigues J
AD  - Department of Pediatrics, Division Allergy & Immunology, Jeffrey Modell 
      Diagnostic Center for Primary Immunodeficiencies, Saint Louis University, St 
      Louis, MO.
FAU - Sorensen, R U
AU  - Sorensen RU
AD  - Department of Pediatrics, Allergy/Immunology Division, Jeffrey Modell Diagnostic 
      Center for Primary Immunodeficiencies, Louisiana State University Health Sciences 
      Center, New Orleans, LA, USA.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150729
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Polysaccharides, Bacterial)
SB  - IM
MH  - Administration, Intravenous
MH  - Adolescent
MH  - Antibodies, Bacterial/*blood
MH  - Child
MH  - Female
MH  - Humans
MH  - Immunoglobulin A/administration & dosage/immunology
MH  - Immunoglobulin G/administration & dosage/immunology
MH  - Immunoglobulin M/administration & dosage/immunology
MH  - Immunoglobulins, Intravenous/*administration & dosage/immunology
MH  - Immunologic Deficiency Syndromes/immunology/microbiology/*therapy
MH  - Injections, Subcutaneous
MH  - Male
MH  - Pneumococcal Infections/immunology/*prevention & control
MH  - Polysaccharides, Bacterial/*immunology
MH  - Streptococcus pneumoniae/*immunology
PMC - PMC4578508
OTO - NOTNLM
OT  - B cell
OT  - antibodies
OT  - immunodeficiency diseases
EDAT- 2015/08/01 06:00
MHDA- 2015/12/19 06:00
PMCR- 2016/10/01
CRDT- 2015/08/01 06:00
PHST- 2015/04/06 00:00 [received]
PHST- 2015/05/29 00:00 [revised]
PHST- 2015/06/07 00:00 [accepted]
PHST- 2015/08/01 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - 10.1111/cei.12665 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2015 Oct;182(1):51-6. doi: 10.1111/cei.12665. Epub 2015 Jul 29.